AR023840A2 - Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad - Google Patents

Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad

Info

Publication number
AR023840A2
AR023840A2 ARP000102123A ARP000102123A AR023840A2 AR 023840 A2 AR023840 A2 AR 023840A2 AR P000102123 A ARP000102123 A AR P000102123A AR P000102123 A ARP000102123 A AR P000102123A AR 023840 A2 AR023840 A2 AR 023840A2
Authority
AR
Argentina
Prior art keywords
diaminopropionate
roxifiban
isoxazolin
pharmaceutical composition
composition containing
Prior art date
Application number
ARP000102123A
Other languages
English (en)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of AR023840A2 publication Critical patent/AR023840A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma polimorfica cristalina 2 del compuesto sal acetato de metil -N3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-N2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (Roxifiban) de la siguiente formula estructural 1 dicho polimorfo sedistin gue por el espectro RMN CP/MAS de 13C ene estado solido deacuerdo con la siguiente figura de la forma 2. se describe asismismo la composicion farmacéutica que lo contiene así como su uso en la preparacion de unmedicamento util para tratar oprevenir trastornos asociados a la adhesion de proteínas solubles.
ARP000102123A 1997-06-16 2000-05-03 Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad AR023840A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4971297P 1997-06-16 1997-06-16
US4963397P 1997-06-16 1997-06-16
US8027898P 1998-04-01 1998-04-01

Publications (1)

Publication Number Publication Date
AR023840A2 true AR023840A2 (es) 2002-09-04

Family

ID=27367578

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102847A AR016070A1 (es) 1997-06-16 1998-06-16 Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein
ARP000102123A AR023840A2 (es) 1997-06-16 2000-05-03 Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102847A AR016070A1 (es) 1997-06-16 1998-06-16 Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein

Country Status (18)

Country Link
US (1) US6306886B1 (es)
EP (1) EP0991630A1 (es)
JP (1) JP2002504153A (es)
KR (1) KR20010013790A (es)
CN (1) CN1259940A (es)
AR (2) AR016070A1 (es)
AU (1) AU751198B2 (es)
CA (1) CA2294047A1 (es)
EA (1) EA200000028A1 (es)
EE (1) EE9900573A (es)
HR (1) HRP980291A2 (es)
HU (1) HUP0004755A3 (es)
IL (1) IL132618A0 (es)
NO (1) NO996182D0 (es)
NZ (1) NZ502077A (es)
PL (1) PL337612A1 (es)
SK (1) SK166699A3 (es)
WO (1) WO1998057939A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
KR102060464B1 (ko) * 2010-05-27 2019-12-30 이 아이 듀폰 디 네모아 앤드 캄파니 4-[5-[3-클로로-5-(트라이플루오로메틸)페닐]-4,5-다이하이드로-5-(트라이플루오로메틸)-3-아이속사졸릴]-n-[2-옥소-2-[(2,2,2-트라이플루오로에틸)아미노]에틸]-1-나프탈렌카르복스아미드의 결정 형태
CA2833645C (en) * 2011-05-17 2019-09-17 Zach System S.P.A. Method of detecting polymorphs using synchrotron radiation
GB2515783B (en) * 2013-07-03 2018-07-11 Rotam Agrochem Int Co Ltd Process for preparing clomazone, a form and use of the same
KR20240037628A (ko) 2022-09-15 2024-03-22 문혜경 그래핀이 함유된 고강도 내열 안경렌즈 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE69426604T2 (de) * 1993-11-24 2001-05-10 Du Pont Pharm Co Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten

Also Published As

Publication number Publication date
EA200000028A1 (ru) 2000-08-28
HUP0004755A3 (en) 2002-10-28
CN1259940A (zh) 2000-07-12
JP2002504153A (ja) 2002-02-05
HUP0004755A2 (hu) 2001-07-30
IL132618A0 (en) 2001-03-19
SK166699A3 (en) 2001-09-11
CA2294047A1 (en) 1998-12-23
NO996182L (no) 1999-12-14
EP0991630A1 (en) 2000-04-12
AU8071998A (en) 1999-01-04
HRP980291A2 (en) 1999-04-30
KR20010013790A (ko) 2001-02-26
EE9900573A (et) 2000-08-15
WO1998057939A1 (en) 1998-12-23
PL337612A1 (en) 2000-08-28
US6306886B1 (en) 2001-10-23
AR016070A1 (es) 2001-06-20
NZ502077A (en) 2002-03-01
NO996182D0 (no) 1999-12-14
AU751198B2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
YU46095A (sh) Postupak pripreme leka za inhalacionu primenu
BR0314372A (pt) Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BR9808540A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
EP1798234A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A TEMOZOLOMIDE ESTER
AR023840A2 (es) Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad
AU5835400A (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
RU94016184A (ru) Противоаллергическая композиция для местного глазного применения, способ ее получения
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
CN114533701B (zh) 一种马钱子碱凝胶贴膏剂及其制备方法和用途
FR2768734B1 (fr) Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE50006842D1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico